OverviewChartNewsTraderScreen

Esperion Therapeutics/  US29664W1053  /

IEX
6/4/2024  9:59:49 PM Chg. +0.03 Volume Bid- Ask10:00:00 PM High Low
2.26USD +1.12% 107,573
Turnover: 235,714.20		 -Bid Size: - 5.00Ask Size: 1,000 2.28 2.14
GlobeNewswire 5/23 Esperion to Participate in Upcoming June Investor Conferences
GlobeNewswire 5/22 First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination w...
GlobeNewswire 5/20 Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterol...
GlobeNewswire 5/14 Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET...
GlobeNewswire 5/10 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 5/7 Esperion Reports First Quarter 2024 Financial Results
GlobeNewswire 5/2 Beyond, Inc. Announces Key Additions to Leadership Team
GlobeNewswire 4/29 Esperion to Participate in Upcoming May Investor Conferences
GlobeNewswire 4/23 Esperion to Report First Quarter 2024 Financial Results on May 7
GlobeNewswire 4/7 Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (...
GlobeNewswire 4/1 Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
GlobeNewswire 3/27 One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors
GlobeNewswire 3/26 Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire 3/25 Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & ...
GlobeNewswire 3/22 U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiova...
GlobeNewswire 3/22 CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose ...
GlobeNewswire 2/27 Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 2/16 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2/13 Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
GlobeNewswire 2/1 RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
GlobeNewswire 1/23 Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ ...
GlobeNewswire 1/19 Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
GlobeNewswire 1/18 Esperion Announces Proposed Public Offering of Common Stock
GlobeNewswire 1/3 Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including...
GlobeNewswire 12/18/2023 Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference